. [eighty two] to evaluate the efficacy, safety and tolerability of Cannabidiol as an adjunct therapy along with anti-epileptic prescription drugs on the individuals struggling from tuberous sclerosis sophisticated whose most popular neurological symptom is epilepsy. Within this scientific trial research, just after therapy with Cannabidiol, respon